- TheStreet.com•11 hours ago
While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.
- Business Wire•12 hours agoAcceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology
Acceleron Pharma Inc. and Celgene Corporation , today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept in patients with lower risk myelodysplastic syndromes at the 58th Annual Meeting of the American Society of Hematology in San Diego, California.
- American City Business Journals•12 hours ago
After paying $100 million in 2013 for the option to buy Boston-based Acetylon Pharmaceuticals and then passing on a deal this August, Celgene purchased part of the cancer drug developer on Friday for an undisclosed sum. Privately-held Acetylon, which has 40 employees, said that it had been acquired by Celgene (Nasdaq: CELG). The deal gives New Jersey-based Celgene worldwide rights to Acetylon’s lead experimental drug candidates, called ricolinostat and citarinostat, for cancer, autoimmune diseases and neurodegenerative disorders.
CELG : Summary for Celgene Corporation - Yahoo Finance
Celgene Corporation (CELG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||117.40 x 400|
|Ask||117.63 x 200|
|Day's Range||117.23 - 119.39|
|52 Week Range||93.05 - 127.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||44.68|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|